LGR5 and hepatocellular carcinoma: Taken together, the identification of HCC patients with high levels of LGR5 using α-LGR5 presents an intriguing biomarker opportunity that both reports the β-catenin mutant subset and supports the use of therapeutic molecules such as α-LGR5-ADC, where drug efficacy is independent of immune infiltration.